Evidence map›Paper›PMID 11870536›Full record

ArticleBritish journal of cancer2002

Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma.

H Shimada, T Hoshino, S Okazumi, H Matsubara, Y Funami, Y Nabeya, H Hayashi, A Takeda, T Shiratori, T Uno and 2 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Molecular mechanisms associated with chemoresistance in esophageal cancer.Cellular and molecular life sciences : CMLS · 2022
    Review
  5. Article
  6. Observational
  7. Multi-panel assay of serum autoantibodies in colorectal cancer.International journal of clinical oncology · 2018
    Article
  8. Article
  9. Article
  10. Article
  11. Gastric cancer and the epoch of immunotherapy approaches.World journal of gastroenterology · 2015
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Novel immunotherapeutic strategies of gastric cancer treatment.Journal of biomedicine & biotechnology · 2011
    Review
  20. Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

H ShimadaDepartment of Academic Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuou-ku, Chiba 260-8677, Japan. hshimada@srgy201.m.chiba-u.ac.jp
T Hoshino
S Okazumi
H Matsubara
Y Funami
Y Nabeya
H Hayashi
A Takeda
T Shiratori
T Uno
H Ito
T Ochiai
Chiba University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ability to predict patients' responses to chemoradiotherapy by analyzing pre-treatment biopsy specimens would be valuable for managing oesophageal squamous-cell cancer. To this end, the expression of p53, thymidine phosphorylase and vascular endothelial cell growth factor was analyzed by immunohistochemistry in 52 patients with oesophageal squamous-cell cancer prior to chemoradiotherapy. Treatment consisted of radiotherapy (40 Gy) and 5 day-infusion of 5-Fluorouracil (500 mg m(-2) per day) combined with cisplatin (10 mg m(-2) per day). Following treatment, imaging and endoscopic reassessment was performed to establish treatment response. Thirty-one patients underwent radical surgery and 21 patients were treated with an additional 20 Gy of radiotherapy. Of the tumours studied, 58% were p53-positive, 40% thymidine phosphorylase-positive and 44% vascular endothelial cell growth factor-positive. A clinical response was observed in 36 patients (69%) and was negatively associated with thymidine phosphorylase expression (P=0.02) and vascular endothelial cell growth factor expression (P<0.001). However, the 5-year survival rate was significantly lower only in patients with vascular endothelial cell growth factor-positive tumours (P=0.037). Multivariate analysis identified vascular endothelial cell growth factor as a significant independent prognostic factor (P=0.0147). These results suggest that expression of angiogenic factors has predictive value for the treatment response and outcome of patients with oesophageal cancer.

Indexed as

Angiogenesis Inducing AgentsCarcinoma, Squamous CellChemotherapy, AdjuvantEndothelial Growth FactorsEsophageal NeoplasmsFemaleHumansImmunoenzyme TechniquesLymphokinesMaleMiddle AgedMultivariate AnalysisPrognosisRadiotherapy, AdjuvantThymidine PhosphorylaseTumor Suppressor Protein p53Angiogenesis Inducing AgentsEndothelial Growth FactorsLymphokinesThymidine PhosphorylaseTumor Suppressor Protein p53Vascular Endothelial Growth Factor AVascular Endothelial Growth Factors

Identifiers

PMID11870536
PMCPMC2375274
OpenAlexW1965953051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.